NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-07-23
Reading HIMS? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a growth-oriented thesis, focusing on expanding revenue and subscriber base. The current state reflects a mix of progress toward long-term goals and recent volatility in performance.
The market currently prices HIMS at a premium compared to its peers, indicating that investors have high expectations for its future performance. The valuation has risen significantly, suggesting that the market is factoring in some level of growth, but there is a slight expectations gap.
HIMS is on track to grow its revenue and subscriber base, with management emphasizing these priorities. However, recent financial performance has been neutral, and there is a near-term risk of missing earnings expectations, which could impact sentiment.
The thesis hinges on the performance of sector bellwethers like HLN, TEVA, and ZTS. If these companies continue to perform well, it could support HIMS. Conversely, any negative guidance from these peers could create headwinds for HIMS.
Overall, HIMS is positioned for potential growth, but faces significant risks in the near term. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings report missed expectations. This miss raises concerns about the company's performance.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Meeting or exceeding this guidance shows strong growth momentum and supports long-term targets.
Confirms:Q2 2026 revenue reported at $680 million or higher.
Disproves:Q2 2026 revenue reported below $680 million.
Why it matters: Better cash flow from operations is key for funding growth and keeping financial health.
Confirms:Net cash from operating activities rose from $89.4 million in Q1 2026.
Disproves:Net cash from operations dropped again. This shows ongoing cash flow problems.
Why it matters: A smaller net loss shows better cost control. It also means more operational efficiency.
Confirms:Net loss reported less than $92.1 million in Q2 2026.
Disproves:Net loss reported greater than $92.1 million in Q2 2026.
Why it matters: Strong revenue growth shows the company is on track with its growth priority. It can boost investor confidence.
Confirms:Q2 revenue growth meets or exceeds 5% year over year.
Disproves:Q2 revenue growth falls below 3% year over year.
Why it matters: The Eucalyptus acquisition could help Hims & Hers reach more customers. We will see if it works.
Confirms:Subscriber count increases by more than 10% in Q2 2026 compared to Q1 2026.
Disproves:Subscriber count grows less than 5% in Q2 2026 compared to Q1 2026.
Why it matters: Better operating income is key for making money in the long run. It shows the company is controlling costs.
Confirms:Operating income improves by at least 10% in Q2 2026 compared to Q1 2026.
Disproves:Operating income falls or stays the same in Q2 2026 compared to Q1 2026.
Why it matters: Higher cash from operations shows improved cash flow. This can enhance financial stability.
Confirms:Cash from operations exceeds $100M in Q2.
Disproves:Cash from operations falls below $80M in Q2.
Why it matters: Fast subscriber growth shows strong demand. It also means good engagement strategies.
Confirms:Subscriber growth was over 9% year-over-year in Q2 2026.
Disproves:Subscriber growth was below 9% year-over-year in Q2 2026.
Why it matters: News about the buyback program shows confidence in the company's value and future.
Confirms:Management will share details about the share buyback program, like timing and amount.
Disproves:No new news about the buyback program after the first announcement.
Why it matters: Good integration will boost Hims & Hers' market presence. It will also help long-term growth.
Confirms:Look for good news on Eucalyptus joining. This includes new products and market growth.
Disproves:News about problems or delays in joining can hurt how well operations work together.
Why it matters: Increasing subscribers shows strong demand and supports revenue growth goals.
Confirms:Subscriber count is above 2.6 million.
Disproves:Subscriber count is below 2.6 million.
Why it matters: Hitting this target shows good operations and helps financial health.
Confirms:Q2 2026 Adjusted EBITDA is $35 million or more.
Disproves:In Q2 2026, Adjusted EBITDA is under $35 million.
